Introduction: 

The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).

Methods: 

The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI.

Results: 

Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models.

Conclusions: 

Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.

中文翻译：

---

前列腺癌、雄激素剥夺疗法的使用和认知障碍：一项基于人群的研究。

介绍： 

来自基于人群的梅奥衰老临床研究 (MCSA) 在男性中确定了前列腺癌和雄激素剥夺疗法(ADT) 的使用与发生轻度认知障碍 (MCI) 的几率之间的关联。

方法： 

该研究包括参加 MCSA 的 2513 名男性（平均年龄 73.1 岁）。使用 Rochester Epidemiology Project 医疗记录关联系统提取前列腺癌史、ADT 使用史和首次 MCSA 就诊前 ADT 暴露时间。MCI 在基线访问时被诊断出来。逻辑回归用于确定前列腺癌和 ADT 的使用是否与 MCI 的几率相关。

结果： 

在 2513 名参与者中，349 人（13.9%）有前列腺癌病史；其中 99 人（28.3%）在 MCSA 入组前接受了 ADT 治疗。有 382 人 (15.2%) 被诊断为 MCI。在单变量逻辑回归模型中，前列腺癌（优势比，1.50；95% 置信区间，1.12-2.00）和 ADT 暴露（优势比，1.57；95% 置信区间，0.96-2.58）与更高的 MCI 优势相关. 这些关联在多变量模型中大大减弱并且不显着。

结论： 

在这项基于人群的横断面研究中，前列腺癌的诊断和 ADT 的使用均与 MCI 的几率无关。